반응식
[N:1]1([C:7]2[N:12]=[CH:11][NH:10][C:9](=[O:13])[CH:8]=2)[CH2:6][CH2:5][NH:4][CH2:3][CH2:2]1.[Cl:14][C:15]1[CH:22]=[C:19]([CH:20]=O)[C:18]([OH:23])=[CH:17][CH:16]=1>>[Cl:14][C:15]1[CH:16]=[CH:17][C:18]([OH:23])=[C:19]([CH:22]=1)[CH2:20][N:4]1[CH2:5][CH2:6][N:1]([C:7]2[N:12]=[CH:11][NH:10][C:9](=[O:13])[CH:8]=2)[CH2:2][CH2:3]1참가 물질
3
실험 절차
6-[4-(5-Chloro-2-hydroxy-benzyl)-piperazin-1-yl]-3H -pyrimidin-4-one was prepared using Procedure B from 6-piperazin-1-yl-3H-pyrimidin-4-one (Intermediate 4) and 5-chlorosalicylaldehyde (available from Aldrich). 1H NMR (400 MHz, CDCl3) δ 2.60-2.64 (m, 4H), 3.58-3.65 (m, 4H), 3.70 (s, 2H), 5.40 (s, 1H), 6.76-6.78 (m, 1H), 6.96-6.99 (m, 1H), 7.13-7.15 (m, 1H), 7.85 (s, 1H), 10.60 (br s, 1H), 12.65 (br s, 1H). Mass spectrum (ES) MH+=321.
출처 및 근거
- ORD 기록
- ord-418fa5ef8346448e9ee6008c35ef388f
- 출처 데이터셋
- uspto-grants-2010_01
- 특허 번호
- US07652013B2
연결된 노트
불러오는 중…